Marker Therapeutics, Inc. provided an update on its Phase 1 APOLLO study of MT-601, a novel T cell therapy targeting relapsed lymphoma patients. The study reported an objective response rate of 78% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback